<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391545</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-145-19</org_study_id>
    <nct_id>NCT02391545</nct_id>
  </id_info>
  <brief_title>A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)</brief_title>
  <official_title>A Two-arm, Phase 1b/2 Study of Duvelisib Administered in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Two-arm, Phase 1b/2 Study of IPI-145 Administered in Combination with Rituximab or
      Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-arm, open-label, Phase 1b/2 trial designed to evaluate the safety and efficacy
      of IPI-145 in combination with rituximab and IPI-145 in combination with obinutuzumab in
      subjects with previously untreated CD20+ FL.

      The study will be conducted in two parts, a Safety Lead-in (Part 1) followed by a randomized,
      2-Stage Design in Part 2. Each treatment arm will be assessed independently for dose limiting
      toxicity (DLT) within Part 1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLTs) - Part 1</measure>
    <time_frame>28 days from first dose of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response Rate (CRR)- Part 2</measure>
    <time_frame>Up to 2 years from the first dose of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Composite measure of safety, as indicated by Treatment-emergent adverse events (TEAEs) and changes in safety laboratory values</measure>
    <time_frame>Up to 30 days after the last dose of study treatment</time_frame>
    <description>Composite measure of safety, as indicated by Treatment-emergent adverse events (TEAEs) and changes in safety laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 2 years from the first dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 2 years from the first dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years from the first dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK): Plasma concentrations of IPI-145 and IPI-656 (metabolite)</measure>
    <time_frame>Every 4 weeks for 16 weeks</time_frame>
    <description>Plasma concentrations of IPI-145 and IPI-656 (metabolite)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>CD20+ Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>IPI-145 and Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules. IPI-145 will be administered orally, twice daily, in 28-day cycles.
Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPI-145 and Obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules.IPI-145 will be administered orally, twice daily, in 28-day cycles.
Obinutuzumab 1000 mg will be administered intravenously (IV) beginning at Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-145 (duvelisib)</intervention_name>
    <description>PI3K Inhibitor</description>
    <arm_group_label>IPI-145 and Rituximab</arm_group_label>
    <arm_group_label>IPI-145 and Obinutuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>IPI-145 and Rituximab</arm_group_label>
    <other_name>Rituxan/MabThera®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <arm_group_label>IPI-145 and Obinutuzumab</arm_group_label>
    <other_name>GAZYVA/GAZYVARO™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CD20+, follicular lymphoma that has not been treated

          -  CD20-immunophenotyping of tumor to document B-cell follicular lymphoma

          -  Stage II disease with bulky disease (≥ 7cm lesion), Stage III, or Stage IV disease

          -  Disease that requires treatment based on the Investigator's opinion (e.g., meets GELF
             criteria)

          -  At least one measurable lesion that is &gt; 1.5 cm in at least one dimension

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;=2 (corresponds to
             Karnofsky Performance Status [KPS] &gt;=60%)

        Exclusion Criteria:

          -  Received systemic treatment for lymphoma such as chemotherapy, immunotherapy,
             radiotherapy, investigational agents, or radioimmunotherapy.

          -  Clinical evidence of transformation to a more aggressive subtype of lymphoma or grade
             3B follicular lymphoma

          -  Severe allergic or anaphylactic reaction to any monoclonal antibody therapy, murine
             protein, or known hypersensitivity to any of the study drugs

          -  Prior allogeneic hematopoietic stem cell transplant

          -  Prior, current or chronic hepatitis B or hepatitis C infection

          -  Human immunodeficiency virus (HIV) infection or Human T Cell Lymphotropic Virus 1
             (HTLV-1) infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kortrijk</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille Cedex 05</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen Cedex 1</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours Cedex 01</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>8097</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>NW1 1BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <disposition_first_submitted>May 2, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 2, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 4, 2018</disposition_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Previously Untreated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

